Stocks making the biggest moves premarket: Snowflake, Moderna, Broadcom & more - CNBC
📉 Moderna shares dropped over 2% in premarket trading after Rothschild & Co Redburn downgraded the stock to a sell rating.
🧬 The downgrade cites concerns that Moderna is currently overvalued following a massive surge linked to its experimental melanoma cancer vaccine trial success.
💊 The article highlights that the recent stock rally was driven by positive trial results for the company's cancer vaccine program.
Risk Factors
- Shares fell more than 2% in premarket trading after Rothschild & Co Redburn downgraded the stock to a sell rating.
- Analysts at Rothschild & Co Redburn stated that Moderna is now overvalued despite recent success with its experimental cancer vaccine trial.
Full Analysis
Moderna (MRNA) shares declined more than 2% in premarket trading following a downgrade from Rothschild & Co Redburn, which changed its rating to sell. The investment firm cited concerns that the stock is now overvalued despite a recent surge driven by successful trial results for an experimental cancer vaccine targeting melanoma.
The article notes that Moderna's stock performance was heavily influenced by the positive reception of its melanoma vaccine trial data, which previously fueled a significant rally. However, the analyst downgrade suggests a shift in valuation perception regarding the company's future prospects and the magnitude of its recent successes.
This news item appears within a broader roundup of premarket movers including Snowflake, Broadcom, and other companies reporting earnings or guidance updates. The specific focus for Moderna is the negative sentiment triggered by the sell rating rather than new fundamental business data like revenue or earnings beats.
